ライフサイエンスコーパス: impaired glucose tolerance

1 17 with impaired fasting glucose and 33 with impaired glucose tolerance).

2 iabetes in high-risk persons (ie, those with impaired glucose tolerance).

3 mpared with sham, but nonresponders retained impaired glucose tolerance.

4 elevated fasting glucose levels and severely impaired glucose tolerance.

5 nylindol-3-yl)-acrylate (UK5099) resulted in impaired glucose tolerance.

6 levels, and adiposity, along with strikingly impaired glucose tolerance.

7 sponsible for hepatic insulin resistance and impaired glucose tolerance.

8 ident HF hospitalization among patients with impaired glucose tolerance.

9 ent type 2 diabetes in Indian Asian men with impaired glucose tolerance.

10 ns in the human paired box gene PAX6 lead to impaired glucose tolerance.

11 tors leads to a decreased beta-cell mass and impaired glucose tolerance.

12 .05), along with a 2-fold higher insulin and impaired glucose tolerance.

13 e nor female C57BL/6J Slc30a8 KO mice showed impaired glucose tolerance.

14 in patients with impaired fasting glucose or impaired glucose tolerance.

15 blood glucose, decreased plasma insulin, and impaired glucose tolerance.

16 n of let-7 results in insulin resistance and impaired glucose tolerance.

17 k of type 2 diabetes mellitus in adults with impaired glucose tolerance.

18 reduced insulin production and secretion and impaired glucose tolerance.

19 2 wk, at which time they developed similarly impaired glucose tolerance.

20 velocity (NCV) and sensory deficits prior to impaired glucose tolerance.

21 ive glucose-stimulated insulin secretion and impaired glucose tolerance.

22 lderly Americans and 30.8 for Americans with impaired glucose tolerance.

23 , which results in systemic inflammation and impaired glucose tolerance.

24 d plasma FFA and insulin concentrations, and impaired glucose tolerance.

25 ed neonatal beta cell expansion and mass and impaired glucose tolerance.

26 ree additional subjects were identified with impaired glucose tolerance.

27 -beta mRNA levels in subjects with normal or impaired glucose tolerance.

28 are prone to greater insulin resistance and impaired glucose tolerance.

29 ncreased risk of diabetes among persons with impaired glucose tolerance.

30 asted and fed mice but paradoxically also in impaired glucose tolerance.

31 the DPP cohort 25 years of age or older with impaired glucose tolerance.

32 ulin secretion in response to glucose and an impaired glucose tolerance.

33 reduce the risk for diabetes in people with impaired glucose tolerance.

34 its prevalence and prevention in those with impaired glucose tolerance.

35 ffect of systemic insulin administration and impaired glucose tolerance.

36 /- mice have normal blood glucose levels but impaired glucose tolerance.

37 hagic immediately after weaning, and exhibit impaired glucose tolerance.

38 leading to peripheral insulin resistance and impaired glucose tolerance.

39 nsulin secretion led to a high prevalence of impaired glucose tolerance.

40 another 37% have impaired fasting glucose or impaired glucose tolerance.

41 iabetes, two indeterminate glycemia, and six impaired glucose tolerance.

42 participants had impaired fasting glucose or impaired glucose tolerance.

43 s on quadriceps muscles from obese mice with impaired glucose tolerance.

44 Moreover, mCaROCK1 mice also displayed impaired glucose tolerance.

45 autoantibody-positive at-risk children with impaired glucose tolerance.

46 ed by the Homeostatic Model Assessment), and impaired glucose tolerance.

47 food intake, reduced energy expenditure, and impaired glucose tolerance.

48 groups, but 65% of participants with CKD had impaired glucose tolerance.

49 e and those with impaired fasting glucose or impaired glucose tolerance.

50 fication of insulin exocytosis, resulting in impaired glucose tolerance.

51 ce are metabolically less efficient and show impaired glucose tolerance.

52 DIO mice, despite FFA2(-/-) mice displaying impaired glucose tolerance.

53 higher fasting glucose levels and moderately impaired glucose tolerance.

54 individuals at high cardiovascular risk with impaired glucose tolerance.

55 ssociated with an increased adjusted odds of impaired glucose tolerance (1.7; 1.3-2.1), diabetes (2.3

56 We analysed data on 749 adults with impaired glucose tolerance (278 men and 471 women, mean

57 The new impaired glucose tolerance 4 (IGT4) model was selected u

58 those without gestational diabetes but with impaired glucose tolerance, a lower carbohydrate intake

59 2 diabetes mellitus/impaired fasting glucose/impaired glucose tolerance, a systolic BP treatment goal

60 ese patients with coronary heart disease and impaired glucose tolerance, acarbose did not reduce the

61 (NAVIGATOR), 9306 research participants with impaired glucose tolerance and >/=1 cardiovascular risk

62 We studied 14 obese children with impaired glucose tolerance and 14 with normal glucose to

63 de content was 2.3-fold higher in those with impaired glucose tolerance and 2.1-fold higher in those

64 Short sleep duration is associated with impaired glucose tolerance and an increased risk of diab

65 ng cassette transporter A1 (ABCA1) result in impaired glucose tolerance and beta-cell dysfunction.

66 th control littermates, knockout mice showed impaired glucose tolerance and circulating leptin, GLP-1

67 fusion of a specific PREP inhibitor, S17092, impaired glucose tolerance and decreased insulin levels

68 Cd39/Entpd1-null mice have impaired glucose tolerance and decreased insulin sensiti

69 zard ratios in patients diagnosed with PTDM, impaired glucose tolerance and diabetes before transplan

70 To date, limited data in subjects with impaired glucose tolerance and diabetes demonstrate nerv

71 ructive sleep apnea (OSA) is associated with impaired glucose tolerance and diabetes, it remains uncl

72 een to identify novel mutations resulting in impaired glucose tolerance and diabetes.

73 Simvastatin-treated patients had an impaired glucose tolerance and displayed a decreased ins

74 MS mice showed impaired glucose tolerance and disturbed sleep.

75 KO mice also have impaired glucose tolerance and elevated fasting insulin

76 Phlebotomy of humans with impaired glucose tolerance and ferritin values in the hi

77 le role for L. rhamnosus in the treatment of impaired glucose tolerance and food intake disorders by

78 tal period, which again correlated with both impaired glucose tolerance and GSIS, although BCM remain

79 ng prevalence of diabetes mellitus, and both impaired glucose tolerance and hypertension are importan

80 k between prediabetic markers, in particular impaired glucose tolerance and insulin resistance, and f

81 ) is, albeit inconsistently, associated with impaired glucose tolerance and insulin resistance.

82 rning fed glucose levels but showed severely impaired glucose tolerance and insulin secretion.

83 a(2+), and mice lacking this channel exhibit impaired glucose tolerance and insulin secretion.

84 ure, hyperinsulinemia, hypertriglyceridemia, impaired glucose tolerance and insulin sensitivity, as w

85 DKO/2 mice, but not DKO/1 mice, also showed impaired glucose tolerance and insulin sensitivity-thoug

86 may have protective role against BW gain and impaired glucose tolerance and lipid metabolism.

87 Impaired glucose tolerance and metabolic syndrome are as

88 Patients with impaired glucose tolerance and new-onset diabetes after

89 n increased risk of weight gain and obesity, impaired glucose tolerance and new-onset diabetes, hyper

90 of lifestyle intervention for patients with impaired glucose tolerance and provide further justifica

91 ose-tolerant mice, and prediabetic mice with impaired glucose tolerance and reduced circulating insul

92 overexpression of Let-7 in mice resulted in impaired glucose tolerance and reduced glucose-induced p

93 ompetent and immune deficient) with severely impaired glucose tolerance and significant loss of adipo

94 cle, leading to postprandial hyperglycaemia, impaired glucose tolerance and T2D.

95 eceptor (NPRC) increased in individuals with impaired glucose tolerance and T2D.

96 ave been recently reported to be elevated in impaired glucose tolerance and type 2 diabetes mellitus

97 Impaired glucose tolerance and type 2 diabetes were indu

98 In a high-fat diet-fed mouse model of impaired glucose tolerance and type 2 diabetes, dibenzaz

99 obese and lean subjects, with both normal or impaired glucose tolerance and type 2 diabetes.

100 , HbA1c [-10 g/L (95% CI: -12.90, -7.10 g/L; impaired glucose tolerance) and -6 g/L (95% CI: -8.47, -

101 eria (NAFLD with impaired fasting glucose or impaired glucose tolerance) and were randomly assigned i

102 rweight and obese normoglycemic (obese), (3) impaired glucose tolerance, and (4) type 2 diabetes mell

103 World Health Organization criteria, 23% with impaired glucose tolerance, and 31% with type 2 diabetes

104 ies typical of T2D, including hyperglycemia, impaired glucose tolerance, and a substantial reduction

105 ine treatment acutely increased food intake, impaired glucose tolerance, and altered physical activit

106 isease are at risk of excessive weight gain, impaired glucose tolerance, and dyslipidemia with subseq

107 HF mice developed obesity, impaired glucose tolerance, and elevated free fatty acid

108 sted in increased body weight and adiposity, impaired glucose tolerance, and elevated insulin levels.

109 hyperinsulinemia to the metabolic syndrome, impaired glucose tolerance, and finally type 2 diabetes

110 s defined as impaired fasting glucose and/or impaired glucose tolerance, and high CVD risk as 10 year

111 tors for hepatic steatosis were male gender, impaired glucose tolerance, and increased body mass inde

112 a high-fat diet develop increased body fat, impaired glucose tolerance, and insulin resistance in th

113 AGM was defined as impaired fasting glucose, impaired glucose tolerance, and new onset diabetes after

114 circulating levels of undercarboxylated OCN, impaired glucose tolerance, and reduced energy expenditu

115 exposure is associated with higher body fat, impaired glucose tolerance, and reduced insulin secretio

116 ly relevant because humans who have obesity, impaired glucose tolerance, and T2DM reportedly have def

117 ns were persons without diabetes, those with impaired glucose tolerance, and those with type 2 diabet

118 e on screening for impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes in asymp

119 supportive-care group had severe infections, impaired glucose tolerance, and weight gain of more than

120 with established coronary heart disease and impaired glucose tolerance, and whether the incidence of

121 Severe infections, impaired glucose tolerance, and/or weight gain in the fi

122 %) were diabetic while a further 55 (2%) had impaired glucose tolerance; and 218 (7%) were current sm

123 Kcne2 deletion in mice impaired glucose tolerance as early as 5 wk of age in pu

124 expressing PGC-1alpha exhibited at adult age impaired glucose tolerance associated with reduced insul

125 of birth, but reduced insulin secretion and impaired glucose tolerance at 6 months of age.

126 rt focuses on 11,827 men without diabetes or impaired glucose tolerance at entry for whom follow-up g

127 lts indicated that despite hyperglycemia and impaired glucose tolerance, B6 mice have lower plasma in

128 individuals at high cardiovascular risk with impaired glucose tolerance, both baseline levels of dail

129 t mice (MKOs), which developed significantly impaired glucose tolerance but showed normal peripheral

130 in children with beta cell autoimmunity and impaired glucose tolerance, but not in children with ear

131 islet-specific Senp1 deletion in mice caused impaired glucose tolerance by reducing the amplification

132 tervention programme for Chinese people with impaired glucose tolerance can reduce incidence of cardi

133 se patients with type 2 diabetes mellitus or impaired glucose tolerance, canakinumab had no effect co

134 rolimus, sirolimus, and tacrolimus/sirolimus impaired glucose tolerance compared to control.

135 ght, adipose mass, adipose inflammation, and impaired glucose tolerance compared with AhR(fl/fl) cont

136 G6PD-deficient mice had smaller islets and impaired glucose tolerance compared with control mice, w

137 to-d-serine ratios were lower in humans with impaired glucose tolerance compared with normal glucose

138 edentary dams produced female offspring with impaired glucose tolerance compared with offspring of ch

139 posity as early as 2 weeks of age as well as impaired glucose tolerance compared with offspring of da

140 results in compromised insulin secretion and impaired glucose tolerance compared with WT mice.

141 mice, resulted in decreased beta cell mass, impaired glucose tolerance, defective insulin secretion,

142 throughout the developing pancreas leads to impaired glucose tolerance, deletion in the beta cell in

143 Indeed, both hyperinsulinemia and impaired glucose tolerance developed spontaneously betwe

144 h-fat diet (HFD), body weight (BW) gain, and impaired glucose tolerance development are associated wi

145 However, these mice exhibited impaired glucose tolerance due in part to reduced expres

146 ated in their pancreatic pericytes exhibited impaired glucose tolerance due to compromised beta-cell

147 n of CaMKII in beta-cells show significantly impaired glucose tolerance due to decreased GSIS.

148 t activity in transgenic animals resulted in impaired glucose tolerance due to defective insulin secr

149 lly identifiable in the prediabetic phase of impaired glucose tolerance, early intervention might pre

150 beta-cell human IAPP (hIAPP) expression had impaired glucose tolerance, elevated islet Il1b mRNA, an

151 dysfunction in patients with prediabetes or impaired glucose tolerance emphasizes the susceptibility

152 ences, knock-out mice showed a significantly impaired glucose tolerance following oral and intraperit

153 ressive hyperglycemia, hyperinsulinemia, and impaired glucose tolerance from 12 weeks of age without

154 28%, whereas HbA1c detected NODAT in 10% and impaired glucose tolerance (from >/=5.7 to <6.5%) in 51%

155 Impaired glucose tolerance, gestational diabetes, and hy

156 re reduced (P < 0.01) during the OGTT in the impaired glucose tolerance groups, indicating that reduc

157 D displayed lower plasma insulin level, less impaired glucose tolerance (GT), and higher plasma T3 co

158 Individuals with impaired glucose tolerance had higher intramyocellular l

159 islet expansion and led to hyperglycemia and impaired glucose tolerance, hallmark features of gestati

160 Some patients with impaired glucose tolerance have a reversal of neuropathi

161 metabolic disease, including hyperglycemia, impaired glucose tolerance, hyperinsulinemia, hepatic st

162 haracterized by obesity, insulin resistance, impaired glucose tolerance, hyperlipidemia, and cardiova

163 t diet resulted in greater fat accumulation, impaired glucose tolerance, hyperlipidemia, increased se

164 However, pups weaned onto high-fat diet had impaired glucose tolerance if their dams were on a high-

165 tudy that overweight and obese subjects with impaired glucose tolerance (IGT(+)) display significant

166 Both impaired glucose tolerance (IGT) (as defined by the 1985

167 individuals with type 2 diabetes (n = 137), impaired glucose tolerance (IGT) (n = 139), and normal g

168 type 2 diabetes (n = 145) or type 2 diabetes/impaired glucose tolerance (IGT) (n = 293) with those of

169 sformed and categorized into quartiles) with impaired glucose tolerance (IGT) and gestational diabete

170 We identified impaired glucose tolerance (IGT) and gestational diabete

171 n was lower (P < 0.001) in subjects with IFG/impaired glucose tolerance (IGT) and IFG/diabetes but di

172 Type 2 diabetes is characterized by impaired glucose tolerance (IGT) and insulin resistance

173 ing glucose (IFG) and compare the results to impaired glucose tolerance (IGT) and normal glucose tole

174 Aging increases the risk of developing impaired glucose tolerance (IGT) and type 2 diabetes.

175 ated with impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) from published prospect

176 Subjects with impaired glucose tolerance (IGT) have increased myocardi

177 Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) identify individuals at

178 nsulin resistance (IR) and inflammation, and impaired glucose tolerance (IGT) in the prediction of DM

179 rdiac dietary fatty acid (DFA) metabolism in impaired glucose tolerance (IGT) is different in men and

180 g glucose (IFG) is more prevalent in men and impaired glucose tolerance (IGT) more prevalent in women

181 Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) often coexist and as su

182 ch were determined; and 32 participants with impaired glucose tolerance (IGT) or diet-controlled type

183 miscategorize up to 40% of individuals with impaired glucose tolerance (IGT) or frank diabetes based

184 Impaired glucose tolerance (IGT) serves as a marker for

185 development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participat

186 ts are also associated with progression from impaired glucose tolerance (IGT) to diabetes and respons

187 disposition index [DI]) in obese youth with impaired glucose tolerance (IGT) versus normal glucose t

188 generation) develop progressive obesity and impaired glucose tolerance (IGT) with aging.

189 lin-sensitive subjects, 10 participants with impaired glucose tolerance (IGT), 11 with T2D, and 8 hea

190 management of renal transplant patients with impaired glucose tolerance (IGT), a risk factor for the

191 sts in identifying impaired fasting glucose, impaired glucose tolerance (IGT), and NODAT.

192 gories: gestational diabetes mellitus (GDM), impaired glucose tolerance (IGT), and normal glucose tol

193 tance without carbohydrate intolerance (IR), impaired glucose tolerance (IGT), and normotensive and h

194 -IR]) in a large group of subjects with NGT, impaired glucose tolerance (IGT), and T2DM.

195 ng to the development of insulin resistance, impaired glucose tolerance (IGT), and type 2 diabetes ar

196 nce (NGT) to impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and type 2 diabetes is

197 ubjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes, u

198 humans with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), or T2DM.

199 diabetes, impaired fasting glucose (IFG), or impaired glucose tolerance (IGT), potentially resulting

200 lucagon levels are observed in subjects with impaired glucose tolerance (IGT).

201 as either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT).

202 tivity associated with future development of impaired glucose tolerance (IGT).

203 antation (NODAT) and ignore the diagnosis of impaired glucose tolerance (IGT).

204 s with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT).

205 ish subjects with type 2 diabetes (n = 137), impaired glucose tolerance (IGT; n = 139), and normal gl

206 TS [normal glucose tolerance (NGT; n = 190), impaired glucose tolerance (IGT; n = 209), and diabetes

207 with normal glucose tolerance [NGT], 48 with impaired glucose tolerance [IGT], and 34 with type 2 dia

208 es (normal glucose tolerance [NGT], n = 712; impaired glucose tolerance [IGT], n = 353; newly diagnos

209 ) subjects classified as glucose intolerant (impaired glucose tolerance [IGT]; n = 17) or treatment-n

210 The ghrelin agonist impaired glucose tolerance immediately after administrat

211 Hyperglycemia, be it secondary to diabetes, impaired glucose tolerance, impaired fasting glucose, or

212 2-month data, OGTT recorded NODAT in 14% and impaired glucose tolerance in 28%, whereas HbA1c detecte

213 The findings indicate a role of H. pylori in impaired glucose tolerance in adults that may be potenti

214 an insulin secretory defect, which exhibits impaired glucose tolerance in association with insulin r

215 Impaired glucose tolerance in betaLPL-KO mice was presen

216 Ritonavir impaired glucose tolerance in control mice but did not e

217 rolonged dosing with compound 26 resulted in impaired glucose tolerance in diet-induced obese (DIO) C

218 found that genetic deletion of A2AARs caused impaired glucose tolerance in mice fed an HFD.

219 antimiR was sufficient to prevent and treat impaired glucose tolerance in mice with diet-induced obe

220 Obesity significantly increases risk of impaired glucose tolerance in pregnancy, but glycemic ef

221 R blockade with the antagonist exendin(9-39) impaired glucose tolerance in WT mice but had no effect

222 gh-fat feeding of sedentary dams resulted in impaired glucose tolerance, increased serum insulin conc

223 s, respectively (both P<0.0001), manifesting impaired glucose tolerance, insulin resistance, and card

224 In humans, impaired glucose tolerance is accompanied by cardiac ste

225 ese data suggest that, in the United States, impaired glucose tolerance is an independent predictor f

226 Impaired glucose tolerance is associated with HI, althou

227 Impaired glucose tolerance is associated with increased

228 Impaired glucose tolerance is common among obese adolesc

229 ect of these interventions on people without impaired glucose tolerance is lacking.

230 carbohydrate during pregnancy combined with impaired glucose tolerance is postulated to result in hi

231 in patients with coronary heart disease and impaired glucose tolerance is unknown.

232 Abnormal glucose tolerance (AGT; diabetes or impaired glucose tolerance) is associated with increased

233 mean difference 0.30 [95% CI 0.18 to 0.42]), impaired glucose tolerance (mean difference 1.31 [0.37 t

234 ish subjects with type 2 diabetes (n = 145), impaired glucose tolerance (n = 148), and normal glucose

235 s (n = 247), undiagnosed diabetes (n = 180), impaired glucose tolerance (n = 477), or normal glucose

236 7 to 2.25]), and the number of patients with impaired glucose tolerance (odds ratio 5.44 [2.63 to 11.

237 In contrast, POMC-Shp2-/- mice displayed impaired glucose tolerance only secondary to their incre

238 tly more predictive than models using either impaired glucose tolerance or conventional CVD risk fact

239 cluded 563 Japanese Americans with normal or impaired glucose tolerance or diabetes but not taking or

240 e severely obese (BMI > 35 kg/m(2)); 50% had impaired glucose tolerance or diabetes.

241 tment might also be useful for patients with impaired glucose tolerance or diabetes.

242 8) met criteria for impaired fasting glucose/impaired glucose tolerance or diabetes.

243 accompanied by systemic insulin resistance; impaired glucose tolerance or diabetes; islet beta cell

244 of the patients and 14% of the controls had impaired glucose tolerance or fasting hyperglycaemia but

245 n oral glucose tolerance test, 196 (15%) had impaired glucose tolerance or impaired fasting glucose a

246 n men or 80 cm or greater in women, and with impaired glucose tolerance or impaired fasting glucose d

247 onset of cardiomyopathy in individuals with impaired glucose tolerance or in patients with type 2 di

248 type 2 diabetes than among those with either impaired glucose tolerance or normal glucose tolerance (

249 We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver

250 Among patients with impaired glucose tolerance or type 2 diabetes, rosiglita

251 e liver (eight subjects) in adolescents with impaired glucose tolerance or type 2 diabetes.

252 efit to individuals, particularly those with impaired glucose tolerance or type 2 diabetes.

253 lar events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g

254 glucose tolerance, impaired fasting glucose/impaired glucose tolerance, or diabetes.

255 ned clinically normal without hyperglycemia, impaired glucose tolerance, or hepatic glycogen depletio

256 no interactions of sex, ethnicity, obesity, impaired glucose tolerance, or S(i) with AST or ALT in t

257 insulin resistance in subjects with obesity, impaired glucose tolerance, or type 2 diabetes and in no

258 risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receiv

259 In Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR)

260 In humans with impaired glucose tolerance, PPARgamma agonist treatment

261 surgical patients and from 38 subjects with impaired glucose tolerance randomized to receive either

262 Lifestyle interventions among people with impaired glucose tolerance reduce the incidence of diabe

263 k and Bmal1 (also called Arntl) mutants show impaired glucose tolerance, reduced insulin secretion an

264 ing, waist circumference, triglyceride, HDL, impaired glucose tolerance, S(i), and AIR, both AST and

265 However, studies of women with impaired glucose tolerance show that replacing refined c

266 lin receptor in BAT transplant mice leads to impaired glucose tolerance, similar to what is seen in n

267 cortical metabolism, as well as chronically impaired glucose tolerance, suggest that disturbed neuro

268 ko mice exhibited fasting hyperglycemia and impaired glucose tolerance test compared with wild-type

269 flammasome activity in aged mice resulted in impaired glucose tolerance that could be attributed to p

270 iabetes mellitus or impaired fasting glucose/impaired glucose tolerance that enrolled at least 100 pa

271 Among research participants with impaired glucose tolerance, there are several easily ide

272 46 were more likely to have progression from impaired glucose tolerance to diabetes than were CC homo

273 eta cell failure underlies the transition of impaired glucose tolerance to overt diabetes; endoplasmi

274 Transition from impaired glucose tolerance to overt hyperglycemia correl

275 P) recruited and randomized individuals with impaired glucose tolerance to treatment with placebo, me

276 oglitazone reduced the risk of conversion of impaired glucose tolerance to type 2 diabetes mellitus b

277 ed-forward loop of glucotoxicity that drives impaired glucose tolerance toward frank type 2 diabetes.

278 glucose/lipid metabolism in 47 patients with impaired glucose tolerance/type 2 diabetes mellitus and

279 s also have higher plasma insulin levels and impaired glucose tolerance upon HFD feeding, relative to

280 enous estrogen, or hypertension therapy; and impaired glucose tolerance), waist circumference, homeos

281 This impaired glucose tolerance was caused by a decrease in i

282 Impaired glucose tolerance was not a prerequisite for th

283 g the first year after renal transplantation.Impaired glucose tolerance was not associated with eithe

284 TB disease progression in guinea pigs with impaired glucose tolerance was similar to that of nondia

285 glucose-tolerant subjects, individuals with impaired glucose tolerance were more insulin resistant,

286 Decreased bodyweight and impaired glucose tolerance were observed as were reduced

287 sease and either type 2 diabetes mellitus or impaired glucose tolerance were randomized to receive pl

288 Working Indian men (aged 35-55 years) with impaired glucose tolerance were randomly assigned (1:1)

289 ese patients with coronary heart disease and impaired glucose tolerance were randomly assigned (1:1),

290 cs in Da Qing, China-serving 577 adults with impaired glucose tolerance-were randomised (1:1:1:1) to

291 +/- mice, but not BALB/cJ Npc1+/- mice, have impaired glucose tolerance when fed a low-fat diet and i

292 iomyopathy in TG9 animals was accompanied by impaired glucose tolerance, which was acutely exacerbate

293 tion on long-term outcomes among adults with impaired glucose tolerance who participated in the Da Qi

294 the progression to diabetes in persons with impaired glucose tolerance who were enrolled in the Diab

295 IGATOR trial involving 9306 individuals with impaired glucose tolerance who were recruited in 40 coun

296 evention Program, treatment of subjects with impaired glucose tolerance with metformin >3.2 years red

297 geted using respective Cre mice: reversible, impaired glucose tolerance with normoglycemia in pancrea

298 ion, we used ABCA1(-l/-l) mice, which showed impaired glucose tolerance without changes in insulin se

299 Participants had impaired glucose tolerance (World Health Organization cr

300 ening test and reserving OGTT for those with impaired glucose tolerance would detect NODAT with a sen